(AOF) – Novacyt announces the finalization of the acquisition by its British subsidiary Novacyt UK of the entire share capital of Yourgene Health plc, an international molecular diagnostics group. The clinical diagnostics specialist specifies that his target “mainly develops, manufactures and markets simple and precise molecular diagnostics and screening solutions for reproductive health and precision medicine”.
Yourgene’s in vitro diagnostic product portfolio includes non-invasive prenatal diagnostics (NIPD) for the detection of trisomy and other genetic disorders, screening tests for cystic fibrosis, invasive rapid tests for aneuploidy and DPYD genotyping. Yourgene is headquartered in Manchester, UK, and the company has offices in Taipei (divestiture pending), Singapore, USA and Canada.
Novacyt believes this acquisition creates a larger, more specialized international diagnostics company, increasing the reach and diversification needed to accelerate its revenue growth and create long-term value.
Dr. John Brown and Lyn Rees, former Chairman and Chief Executive Officer of Yourgene, respectively, will join Novacyt’s Board of Directors as non-executive and executive members, first as non-voting members and then as as full members, subject to ratification by the shareholders at the next general meeting.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Biotechs put to the test
These companies are suffering from a much less favorable economic cycle, which is reflected in particular by a drop in venture capital financing of start-ups. These companies are therefore obliged to carry out redundancy plans. Added to this is a much more restrictive regulatory framework. First, in the United States, the measures linked to the Inflation Reduction Act (IRA) could have a strong impact on the margins of the participants. Indeed, from 2026, the federal Medicare program will be able to renegotiate the price of drugs marketed for nine years (chemical) or 13 years (biological), with discounts that could range from 35 to 60% for biotechs. Likewise, in Europe, with the new drug regulations presented in Brussels in April, the duration of patent protection will be reduced if the innovative treatment is not marketed in all member countries within two years.